Episurf Medical Ab Class B · OMXSTO:EPIS_B

Episurf Medical Ab Class B — Q2 2022 Earnings Presentation

14 slides from Episurf Medical Ab Class B's earnings presentation, Jul 15, 2022

  1. Slide 1: Q2 2022 Presentation

    Q2 2022 Presentation Stockholm, July 15th, 2022 Pål Ryfors, CEO episurf.com

  2. Slide 2: COVID-19 remarks

    COVID-19 remarks • Overall – positive development! • As expected, 2022 started in a challenging way but improvements during late March • Improvement in overall situation continued in Q2 • Significant pandemic-related backlogs (total joint patients, hip & knee)  MRI slots • Hospital visits still sub

  3. Slide 3: Q2 2022 – Highlights: Customer base is growing

    Q2 2022 – Highlights: Customer base is growing • 72% growth in active customer base  Definition: A surgeon ordering at least 1 Episealer® implant during relevant period • Second quarter with strong growth and new quarterly record (43) • Long-term target about 14 Episealer®’s a year – assuming ~50%

  4. Slide 4: Q2 2022 – Highlights: Why focus on customer growth?

    Q2 2022 – Highlights: Why focus on customer growth? Calculation example only • 72% growth in active customer base  Definition: A surgeon ordering at least 1 Episealer® implant during relevant period • Second quarter with strong growth and new quarterly record (43) • Long-term target about 14 Episea

  5. Slide 5: Q2 2022 results

    Q2 2022 results • Highlights Q2 2022  Gross order intake amounted to SEK 2.0m (1.4) • Gross order intake at time of order of fully customized implant and kit  Group net sales amounted to SEK 1.9m (2.0) • Invoicing at the time of surgery – very volatile during the pandemic  Loss for the period amo

  6. Slide 6: Q2 2022 Highlights

    Q2 2022 Highlights • Commercial and clinical milestones  5-year data presented at several clinical congresses • Larger data sets, more surgeons  Promising results from comparative study with Episealer® were accepted for presentation at German orthopaedic congress  Prospective investigator-initiat

  7. Slide 7: Creating a global commercial foundation – Update

    Creating a global commercial foundation – Update Comment +15 India First surgery scheduled following surgeon visits in Q1 countries LTM Saudi Arabia First surgery performed UK Second IPAC meeting held and first patients through Ideal Med under review Unmet Australia First surgeon visits held and KOL

  8. Slide 8: Focus areas going forward

    Focus areas going forward Market 2022 2023 2024 2025 opportunity Strong customer Episealer® Knee Europe Increased commercial focus based & RoW on available data ~USD 0.4bn growth Patient Episealer® Knee US Patient follow-up PMA process ~USD 0.6bn recruitment Product launch and initial Episealer® Tal

  9. Slide 9: Focus areas going forward

    Focus areas going forward Market 2022 2023 2024 2025 opportunity Episealer® Knee Europe Increased commercial focus based ~USD 0.4bn & RoW on available data W-I-P… Patient Episealer® Knee US Patient follow-up PMA process ~USD 0.6bn recruitment Product launch and initial Episealer® Talus studies Epise

  10. Slide 10: Focus areas going forward

    Focus areas going forward Market 2022 2023 2024 2025 opportunity Episealer® Knee Europe Increased commercial focus based ~USD 0.4bn & RoW on available data Patient Episealer® Knee US Patient follow-up PMA process ~USD 0.6bn recruitment 10 Pts. Episealer® Talus Europe Product launch and initial Epise

  11. Slide 11: Focus areas going forward

    Focus areas going forward Market 2022 2023 2024 2025 opportunity Episealer® Knee Europe Increased commercial focus based ~USD 0.4bn & RoW on available data Patient Episealer® Knee US Patient follow-up PMA process ~USD 0.6bn recruitment Product launch and initial Episealer® Talus studies Episealer® T

  12. Slide 12: Focus areas going forward

    Focus areas going forward Market 2022 2023 2024 2025 opportunity Episealer® Knee Europe Increased commercial focus based ~USD 0.4bn & RoW on available data Patient Episealer® Knee US Patient follow-up PMA process ~USD 0.6bn recruitment Product launch and initial Episealer® Talus studies Episealer® T

  13. Slide 13: Shareholders

    Shareholders Shares (000s) % holding Shareholders, Q2 2022 A B votes capital 1 Health Runner AB (Ilija Batljan) -- 34 771 13,0% 13,0% 2 Rhenman Partners -- 12 668 4,7% 4,8% 3 Fjärde AP-Fonden -- 12 537 4,7% 4,7% 4 Sebastian Jahreskog -- 11 089 4,1% 4,2% 5 Tredje AP-Fonden -- 9 980 3,7% 3,7% 6 LMK Fo

  14. Slide 14: Thank you!

    Q2 2022 Presentation Thank you! Stockholm, July 15th, 2022 Pål Ryfors, CEO episurf.com

Episurf Medical — Q2 2022 Earnings Presentation on 6ix